Who are Mycophenolate Mofetil Cap./Tab.'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Mycophenolate mofetil Tablet/Capsule, Mycophénolate Mofétil, Mycophenolate Na, Myfortic Escalation, Mycophenolate Mofeti, Mycophenolate Mofetil (MMF).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/mycophenolate-mofetil-cap-tab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Mycophenolate Mofetil Cap./Tab. — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Mycophenolate Mofetil Cap./Tab. (Mycophenolate Mofetil Cap./Tab.) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Inosine monophosphate dehydrogenase (IMPDH) inhibitor; immunosuppressant. Area: Immunology; Transplantation.

marketed Inosine monophosphate dehydrogenase (IMPDH) inhibitor; immunosuppressant IMPDH type II (inosine monophosphate dehydrogenase) Immunology; Transplantation Small molecule Live · refreshed every 30 min

Target snapshot

Mycophenolate Mofetil Cap./Tab. (Mycophenolate Mofetil Cap./Tab.) — Chong Kun Dang Pharmaceutical. Mycophenolate mofetil inhibits inosine monophosphate dehydrogenase (IMPDH), selectively suppressing T and B lymphocyte proliferation to prevent organ rejection and autoimmune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Mycophenolate Mofetil Cap./Tab. TARGET	Mycophenolate Mofetil Cap./Tab.	Chong Kun Dang Pharmaceutical	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor; immunosuppressant	IMPDH type II (inosine monophosphate dehydrogenase)
Mycophenolate mofetil Tablet/Capsule	Mycophenolate mofetil Tablet/Capsule	Chong Kun Dang Pharmaceutical	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor; immunosuppressant	IMPDH type II (inosine monophosphate dehydrogenase)
Mycophénolate Mofétil	Mycophénolate Mofétil	University Hospital, Limoges	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor	IMPDH type II
Mycophenolate Na	Mycophenolate Na	Sanofi	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor	IMPDH type II
Myfortic Escalation	Myfortic Escalation	East Carolina University	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor	IMPDH type II
Mycophenolate Mofeti	Mycophenolate Mofeti	National Cancer Institute (NCI)	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor	IMPDH type II
Mycophenolate Mofetil (MMF)	Mycophenolate Mofetil (MMF)	ITB-Med LLC	marketed	Inosine monophosphate dehydrogenase (IMPDH) inhibitor	IMPDH type II

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Inosine monophosphate dehydrogenase (IMPDH) inhibitor; immunosuppressant class)

Chong Kun Dang Pharmaceutical · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Mycophenolate Mofetil Cap./Tab. — Competitive Intelligence Brief. https://druglandscape.com/ci/mycophenolate-mofetil-cap-tab. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing